C
지투지바이오
456160KOSDAQ의약품 제조업53.0 / 100
Reference Date: 2026-04-13
Financial Score19.5 / 40
News Sentiment17.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 40.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
GTJ Bio is a leading company in microsphere technology for prolonged-release pharmaceuticals, utilizing its InnoLAMP platform to develop drugs for various diseases and offering CDO/CDMO services. Its key products, including GB-7001, GB-5001, and GB-6002, are undergoing clinical trials in collaboration with global pharmaceutical companies, supported by patented technology and large-scale production capabilities that create high entry barriers.
Number of Employees
48people
Average Salary
125.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
—Industry Average 1.043.5Point
ROE
—Industry Average 4.423.5Point
Debt Ratio
3.69Industry Average 11.986.5Point
Half of industry avg (excellent)
Trend 2024~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼45.0% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼13.4% (1-year basis)
ROE Trend
2.0 / 4
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 70
- Positive지투지바이오, 경영진 4인 2888주 장내매수…"책임경영 실천"
지투지바이오 경영진 4인이 책임경영 실천을 위해 2888주를 장내 매수했습니다.
Detailed Momentum
52-week position5.0Point
52w mid range (45%)
Current 71,200Won52-week high 118,80052-week low 31,283
1-month return0.0Point
1m -40.07% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
16 totalPositive 0Neutral 16Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26